Cargando…

Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors

Background: Blockade of programmed death 1 (PD-1), an inhibitory T lymphocyte receptor, is associated with immune system enhancement and tumor remission in various tumors. We assessed the anti-tumor activity and immune correlates of cancer patients treated with an anti-PD-1 antibody. Patients and Me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Chang, Cai, Xiuyu, Zhang, Hongxia, Xia, Xiaojun, Zhang, Bei, Xia, Liangping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743729/ https://www.ncbi.nlm.nih.gov/pubmed/29290787 http://dx.doi.org/10.7150/jca.21414

Ejemplares similares

Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies
por: Yang, Richard K., et al.
Publicado: (2020)

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
por: Miao, Diana, et al.
Publicado: (2018)

Dynamic imaging and pathological changes in pig liver after MR-guided microwave ablation
por: Dong, Jun, et al.
Publicado: (2018)

Effectiveness and Safety of Apatinib Plus Programmed Cell Death Protein 1 Blockades for Patients with Treatment-refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study
por: Li, Shenglong, et al.
Publicado: (2023)

Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors
por: Wu, Qiuyu, et al.
Publicado: (2023)

An exploratory study of CT-guided percutaneous radiofrequency ablation for stage I thymoma
por: Dong, Jun, et al.
Publicado: (2019)

Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells
por: Kamata, Toshiko, et al.
Publicado: (2016)

Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma
por: Yang, Guozhen, et al.
Publicado: (2021)

Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
por: Oncale, Melody B, et al.
Publicado: (2017)

Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?
por: Lin, Andy Yingjie, et al.
Publicado: (2015)

Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer
por: Yin, Chenxi, et al.
Publicado: (2014)

Combination immunotherapy with interleukin‐2 surface‐modified tumor cell vaccine and programmed death receptor‐1 blockade against renal cell carcinoma
por: Zhang, Xinji, et al.
Publicado: (2018)

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
por: Ricciuti, Biagio, et al.
Publicado: (2020)

Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors
por: Liu, Min, et al.
Publicado: (2020)

Overcoming immune checkpoint blockade resistance in solid tumors with intermittent ITK inhibition
por: Zhao, Manzhi, et al.
Publicado: (2023)

Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes
por: Guo, Guifang, et al.
Publicado: (2019)

Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma
por: Lin, Xiuyun, et al.
Publicado: (2018)

Inhibiting the inhibitors: Checkpoints blockade in solid tumors
por: Mavilio, Domenico, et al.
Publicado: (2013)

Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers
por: Mouri, Atsuto, et al.
Publicado: (2021)

Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy
por: Wang, Yiming, et al.
Publicado: (2018)

Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors
por: Li, Yangyang, et al.
Publicado: (2021)

Intrinsic features of the cancer cell as drivers of immune checkpoint blockade response and refractoriness
por: Ursino, Chiara, et al.
Publicado: (2023)

Successful Outcome of Programmed Death 1 Blockade Plus GemOx for Epstein-Barr Virus-Associated Primary Nodal T/NK Cell Lymphoma: A Case Report
por: Xia, Liang, et al.
Publicado: (2021)

Renin–angiotensin system blockade for the risk of cancer and death
por: Shen, Jian, et al.
Publicado: (2016)

Editorial: Targeting metabolism to activate T cells and enhance the efficacy of checkpoint blockade immunotherapy in solid tumors
por: Xia, Zhijia, et al.
Publicado: (2023)

Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors
por: Hao, Xingxing, et al.
Publicado: (2021)

Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma
por: McCaughan, Georgia J. B., et al.
Publicado: (2016)

Programmed Cell Death-1/Programmed Death-Ligand 1 Blockade Improves Survival of Animals with Sepsis: A Systematic Review and Meta-Analysis
por: Zhang, Qiang, et al.
Publicado: (2018)

A BIVALENT TIM-3/PD-1 BISPECIFIC ANTIBODY FOR THE TREATMENT OF PD-1 ANTIBODY RESISTANT OR REFRACTORY SOLID TUMORS
por: Luan, Yan, et al.
Publicado: (2023)

Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade
por: Guan, Yaping, et al.
Publicado: (2022)

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
por: Beattie, Jason, et al.
Publicado: (2021)

Metabolomic adaptations and correlates of survival to immune checkpoint blockade
por: Li, Haoxin, et al.
Publicado: (2019)

Diagnostic role and immune correlates of programmed cell death-related genes in hepatocellular carcinoma
por: He, Zhanao, et al.
Publicado: (2023)

In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
por: Bartee, Eric, et al.
Publicado: (2017)

Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer
por: Liu, Shousheng, et al.
Publicado: (2019)

Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma
por: Lomphithak, Thanpisit, et al.
Publicado: (2021)

Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
por: Ruan, Ruiwen, et al.
Publicado: (2023)

A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors
por: Wei, Xiao‐Li, et al.
Publicado: (2020)

Improving the synergistic combination of programmed death‐1/programmed death ligand‐1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment
por: Mudassar, Faiqa, et al.
Publicado: (2022)

Non-synergy of PD-1 blockade with T-cell therapy in solid tumors
por: Davies, John S, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5c3ah829v6ub56ej71729jmd7q